Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: MPN (Myeloproliferative Neoplasms)
Age: Between 18 - 80 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required